About InnAVasc
InnAVasc is a company based in Durham (United States) founded in 2013 was acquired by W. L. Gore & Associates in August 2022. InnAVasc has raised $3.34 million across 12 funding rounds from investors including W. L. Gore & Associates, Duke University and HHS. InnAVasc offers products and services including InnAVasc Arteriovenous Graft. InnAVasc operates in a competitive market with competitors including TISSIUM, Laminate Medical, Vivasure Medical, Cardival Medical and Saranas, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Innavasc Medical, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.34 M (USD)
in 12 rounds
-
Latest Funding Round
$1 M (USD), Debt – Conventional
Nov 09, 2021
-
Investors
W. L. Gore & Associates
& 5 more
-
Employee Count
Not available
-
Acquired by
W. L. Gore & Associates
(Aug 16, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InnAVasc
InnAVasc offers a comprehensive portfolio of products and services, including InnAVasc Arteriovenous Graft.
Reduces complications and bleeding during hemodialysis treatments.
People of InnAVasc
Unlock access to complete
Unlock access to complete
Funding Insights of InnAVasc
InnAVasc has successfully raised a total of $3.34M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $1 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InnAVasc
InnAVasc has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include W. L. Gore & Associates, Duke University and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
Biotech startups are incubated and funded in North Carolina.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for InnAVasc
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InnAVasc
Investment portfolio details for InnAVasc
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InnAVasc
Detailed financials for InnAVasc
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Innavasc Comparisons
Peer comparison for InnAVasc
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InnAVasc
InnAVasc operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TISSIUM, Laminate Medical, Vivasure Medical, Cardival Medical and Saranas, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vascular sealants for open surgery are developed by TISSIUM.
|
|
| Locked | Locked | Locked |
AV fistula maturation and patency are supported by VasQ device.
|
|
| Locked | Locked | Locked |
Bioabsorbable implants and delivery systems for arteriotomy closure are developed.
|
|
| Locked | Locked | Locked |
A device for vascular access management is developed.
|
|
| Locked | Locked | Locked |
A device is developed for detecting internal bleeding during catheterization.
|
|
| Locked | Locked | Locked |
Regenerative medicine products are developed for orthopedic and cardiovascular applications.
|
Detailed competitors of InnAVasc
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Innavasc
Complete news archive for InnAVasc
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InnAVasc
InnAVasc was founded in 2013 and raised its 1st funding round 1 year after it was founded.
InnAVasc is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
InnAVasc is a funded company, having raised a total of $3.34M across 12 funding rounds to date.
InnAVasc Medical was founded in 2013 by Duke University surgeoninventors and is located in Durham, United States. Medical devices focused on vascular access for hemodialysis are designed and developed by the company. The initial product consists of a synthetic graft featuring two penetration-resistant chambers, one for outbound blood flow and one for inbound, each with self-sealing windows for needle punctures. FDA 510(k) clearance was granted in December 2014.
InnAVasc's top competitors include TISSIUM, Vivasure Medical and Cardival Medical.
InnAVasc offers InnAVasc Arteriovenous Graft.
InnAVasc has 6 investors. Key investors include W. L. Gore & Associates, Duke University, HHS, NCBiotech, and America’s Seed Fund.